Blood coagulation system state in breast cancer patients that recovered from coronaviral infection after undergoing antitumor medical treatment

Purpose of the study. An analysis of parameters of the blood coagulation system in breast cancer patients after coronavirus disease.

Materials and methods. 50 breast cancer patients were divided into groups: the main group included 30 patients after coronavirus disease, the control group 1–20 patients without confirmed COVID‑19, and control group 2–20 non-cancer women after corona‑ virus disease. All cancer patients received appropriate chemotherapy. The following parameters were studied: activated partial thromboplastin time (APTT), prothrombin time (PT), international normalized ratio (INR), prothrombin index (PTI), fibrinogen, soluble fibrin monomer complexes (SFMCs), thrombin time (TT), antithrombin III, D-dimer and plasminogen, fibrin degradation products. Blood tests were performed 4–6 weeks after the infection and two negative PCR test results for COVID‑19.

Results. Patients of the main group demonstrated differences in INR values after treatment in the subgroups with asymptomatic disease (Me = 1.24) and with mild symptoms (Me = 0.97) U = 10; Z = 2.766; р = 0.0057, in subgroups with asymptomatic disease (Me = 1.24) and with moderate to severe symptoms (Me = 0.98) U = 26.5; Z = 2.199; р = 0.027, and in TT values in subgroups with asymptomatic disease (Me = 14.5) and with moderate to severe symptoms (Me = 16.5) U = 18.5; Z = –2.725; р = 0.0064. The comparison of the parameters in patients after COVID‑19 before (Me = 0.83) and after treatment (Me = 0.4) showed differences in the D-dimer values in patients with moderate to severe disease U = 6.5; Z = –2.2861; р = 0.022 towards their decrease after the therapy. Differences were found in APTT values between the main group (Me = 30.65) and control group 1 (Me = 27.85) U = 119; Z = 3.574; р = 0.00035, in antithrombin values between the main group (Me = 94) and control group 1 (Me = 106) U = 112; Z = 3.713; р = 0.00021, and in SFMCs values between the main group (Me = 17) and control group 1 (Me = 8) U = 180.5; Z = 2.356; р = 0.018.

Conclusions. Determination of plasminogen levels can become an independent factor in detecting thrombotic risk in cancer patients who recovered from COVID‑19. Previous infection with COVID‑19 should be considered an additional risk factor for venous thromboembolic complications for cancer patients.

1. Langer F, Kluge S, Klamroth R, Oldenburg J. Coagulopathy in COVID-19 and Its Implication for Safe and Efficacious Thromboprophy laxis. Hamostaseologie. 2020 Aug;40(3):264–269. https://doi.org/10.1055/a-1178-3551

2. Bangash MN, Patel J, Parekh D. COVID-19 and the liver: little cause for concern. Lancet Gastroenterol Hepatol. 2020 Jun;5(6):529– 430. https://doi.org/10.1016/S2468-1253(20)30084-4

3. Driggin E, Madhavan MV, Bikdeli B, Chuich T, Laracy J, Biondi-Zoccai G, et al. Cardiovascular Considerations for Patients, Health Care Workers, and Health Systems During the COVID-19 Pandemic. J Am Coll Cardiol. 2020 May 12;75(18):2352–2371. https://doi.org/10.1016/j.jacc.2020.03.031

4. Mehta P, McAuley DF, Brown M, Sanchez E, Tattersall RS, Manson JJ, et al. COVID-19: consider cytokine storm syndromes and im munosuppression. Lancet. 2020 Mar 28;395(10229):1033–1034. https://doi.org/10.1016/S0140-6736(20)30628-0

5. Lazzaroni MG, Piantoni S, Masneri S, Garrafa E, Martini G, Tincani A, et al. Coagulation dysfunction in COVID-19: The interplay be tween inflammation, viral infection and the coagulation system. Blood Rev. 2021 Mar;46:100745. https://doi.org/10.1016/j.blre.2020.100745

6. Kuderer NM, Choueiri TK, Shah DP, Shyr Y, Rubinstein SM, Rivera DR, et al. Clinical impact of COVID-19 on patients with cancer (CCC19): a cohort study. Lancet. 2020 Jun 20;395(10241):1907–1918. https://doi.org/10.1016/S0140-6736(20)31187-9

7. Wu Z, McGoogan JM. Characteristics of and Important Lessons From the Coronavirus Disease 2019 (COVID-19) Outbreak in China: Summary of a Report of 72 314 Cases From the Chinese Center for Disease Control and Prevention. JAMA. 2020 Apr 7;323(13):1239– 1242. https://doi.org/10.1001/jama.2020.2648

8. Dzhalilova DSh, Makarova OV. Molecular biological mechanisms of the relationship of hypoxia, inflammatory and immune reac tions. Immunologiya. 2019;40(5):97–105. (In Russ.). https://doi.org/10.24411/0206-49522019-15010

9. Kit OI, Franciyanc EM, Dimiriadi SN, Kaplieva IV, Trepitaki LK. Neoangiogenesis and fibrinolytic system biomarkers expression in the dynamics of experimental kidney ischemia in rats. Experimental and Clinical Urology. 2015;(1):20–23. (In Russ.).

10. Levi M, van der Poll T. Inflammation and coagulation. Crit Care Med. 2010 Feb;38(2 Suppl):S26–34. https://doi.org/10.1097/CCM.0b013e3181c98d21

11. Lazzaroni MG, Piantoni S, Masneri S, Garrafa E, Martini G, Tincani A, et al. Coagulation dysfunction in COVID-19: The interplay be tween inflammation, viral infection and the coagulation system. Blood Rev. 2021 Mar;46:100745. https://doi.org/10.1016/j.blre.2020.100745

12. Kirwan CC, Descamps T, Castle J. Circulating tumour cells and hypercoagulability: a lethal relationship in metastatic breast cancer. Clin Transl Oncol. 2020 Jun;22(6):870–877. https://doi.org/10.1007/s12094-019-02197-6

13. Somonova OV, Antuh EA, Dolgushin BI, Elizarova AL, Sakaeva DD, Selchuk VYu, et al. Practical recommendations for the prevention and treatment of thromboembolic complications in cancer patients. Malignant tumours. 2020;10(3s2-2):131–140. (In Russ.). https://doi.org/10.18027/2224-5057-2020-10-3s2-47

14. Mego M, Karaba M, Minarik G, Benca J, Sedlácková T, Tothova L, et al. Relationship between circulating tumor cells, blood coagu lation, and urokinase-plasminogen-activator system in early breast cancer patients. Breast J. 2015 Apr;21(2):155–160. https://doi.org/10.1111/tbj.12388

15. Ruf W, Rothmeier AS, Graf C. Targeting clotting proteins in cancer therapy – progress and challenges. Thromb Res. 2016 Apr;140 Suppl 1:S1–7. https://doi.org/10.1016/S0049-3848(16)30090-1

16. Vladimirova LYu, Storozhakova AE, Snezhko TA, Strakhova LK, Abramova NA, Kabanov SN, et al. Hormone-positive HER2-nega tive metastatic breast cancer: decision making in real clinical practice. South Russian Journal of Cancer. 2020;1(2):46–51. (In Russ.). https://doi.org/10.37748/2687-0533-2020-1-2-6

17. Colditz GA, Bohlke K. Priorities for the primary prevention of breast cancer. CA Cancer J Clin. 2014 Jun;64(3):186–194. https://doi.org/10.3322/caac.21225

18. Vykhristyuk YuV, Roitberg GE, Dorosh JV, Karaseva NV, Akobova RA. Preventive measures against development of breast cancer. South Russian Journal of Cancer. (In Russ.). 2021;2(1):50–56. https://doi.org/10.37748/2686-9039-2021-2-1-6

19. Walker AJ, Card TR, West J, Crooks C, Grainge MJ. Incidence of venous thromboembolism in patients with cancer – a cohort study using linked United Kingdom databases. Eur J Cancer. 2013 Apr;49(6):1404–1413. https://doi.org/10.1016/j.ejca.2012.10.021